10.17863/CAM.10081
Alberici, Federico
Smith, Rona M
Fonseca, Mariana
Willcocks, Lisa C
Jones, Rachel B
Holle, Julia U
Wieczorek, Stefan
Neumann, Thomas
Martorana, Davide
Gregorini, Gina
Sinico, Renato A
Bruchfeld, Annette
Gunnarsson, Iva
Ohlsson, Sophie
Baslund, Bo
Tesar, Vladimir
Hruskova, Zdenka
Cid, Maria C
Vaglio, Augusto
Lyons, Paul
0000-0001-7035-8997
Smith, Kenneth
0000-0003-3829-4326
Jayne, David
0000-0002-1712-0637
Association of a TNFSF13B (BAFF) regulatory region single nucleotide polymorphism with response to rituximab in antineutrophil cytoplasmic antibody–associated vasculitis
Apollo - University of Cambridge Repository (staging)
2017
Apollo - University of Cambridge Repository (staging)
Apollo - University of Cambridge Repository (staging)
2017-05
Article
0091-6749
1097-6825
Rituximab is effective at inducing and maintaining remission in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). The wide interpatient variability in the duration of B-cell depletion and time to relapse as well as the significant relapse risk after treatment, costs, and adverse event rates necessitate improved patient stratification.
This study was supported by the National Institute of Health Research Cambridge Biomedical Research Centre (http://www.cambridge-brc.org.uk). F.A. has been supported by a European Renal Association-European Dialysis and Transplant Association long-term fellowship between September 2012 and September 2013. A.V. and D.M. were supported by the grant “A tailored approach to the immune monitoring and clinical management of viral and autoimmune diseases,” given by the Regione Emilia-Romagna within the Programma di Ricerca Regione-Università 2010–12.